Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to M1 Kliniken AG
First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 28,00. Zusammenfassung: Der geprüfte Geschäftsbericht 2024 bestätigte die vorläufigen Zahlen und zeigte durchweg gute Ergebnisse, wobei das EBIT unsere Prognose um 13% übertraf. Der Konzernumsatz übertraf €339 Mio. (+7% J/J) und umfasste €92 Mio. Umsatz im Beauty-Segment (+30%) sowie einen Umsatz von €247 Mio. im Handel (+1%). Die KPIs des ersten Quartals bauten auf der positiven Geschäftsdynamik des letzten Jahres auf, mit einem Anstieg des Konzernumsatzes um 10% J/J auf €93 Mio. Angeführt wurde diese Entwicklung von einem Umsatzanstieg von 4% J/J auf €26 Mio. im Beauty-Segment, der zu einem Anstieg des Segment-EBIT um 24% J/J auf €7 Mio. führte. Das Unternehmen wird der Hauptversammlung im Sommer erneut eine Dividende von €0,50 vorschlagen. Die Geschäftsleitung von M1 strebt für 2025 eine weitere Expansion im In- und Ausland an und bestätigte auch, dass das Unternehmen nicht von den aktuellen geopolitischen Unruhen betroffen ist. Dies untermauert unsere Ansicht, dass das Geschäft von M1 mit erschwinglichen Injektionsmitteln so aufgebaut ist, dass es auch in wirtschaftlich schwierigen Zeiten gut entwickelt, und wir behalten unsere Kaufempfehlung mit einem unveränderten Kursziel von €28 bei (93% Aufwärtspotenzial). First Berlin Equity Research has published a research update on M1 Kliniken AG (ISIN: DE000A0STSQ8). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 28.00 price target. Abstract: Audited 2024 reporting confirmed prelims and showed good results across the board highlighted by a 13% EBIT beat to FBe. The group topline eclipsed €339m for the year (+7% Y/Y) and included €92m in Beauty segment sales (+30%) plus Trade turnover of €247m (+1%). Meanwhile, Q1 KPI’s build upon the positive business momentum witnessed last year with group sales up 10% Y/Y to €93m. This was spearheaded by a 4% rise in Beauty segment turnover to €26m spurring a 24% rise in segment EBIT to €7m. The company will again propose a €0.5 dividend to the AGM this summer. M1 brass are calling for more domestic and international expansion in 2025 and confirmed that the business is not exposed to the current geopolitical turmoil. This supports our view that M1's affordable injectables business is built to perform well even when economies struggle, and we remain Buy-rated on M1 with a €28 TP (Upside: 93%). Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse. You can download the research here: http://www.more-ir.de/d/32880.pdf Contact for questions: First Berlin Equity Research GmbH Herr Gaurav Tiwari Tel.: +49 (0)30 809 39 686 web: www.firstberlin.com E-Mail: g.tiwari@firstberlin.com
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
2157774 19.06.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.